This is a news story, published by Gizmodo, that relates primarily to Novo Nordisk’s news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Gizmodo, you can click here:
more news from GizmodoOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
semaglutide. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest different drug candidates news, insulin news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
popular drugs OzempicGizmodo
•81% Informative
At a recent scientific conference, drug companies showed off a variety of next-generation drugs for obesity and type 2 diabetes.
Some of these treatments might help people lose even more weight than current forerunners like Novo Nordisk’s semaglutide.
Other treatments may come with fewer side effects or be easier to take.
The American Diabetes Association held its annual conference over the past weekend .
VR Score
78
Informative language
75
Neutral language
49
Article tone
semi-formal
Language
English
Language complexity
54
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
5
Source diversity
4
Affiliate links
no affiliate links